Anormed President and CEO Michael Abrams Steps Down

May 24, 2006

Vancouver, B.C. – The Board of Directors of AnorMED Inc. (TSX:AOM, AMEX:AOM) today announced that Dr. Mike Abrams has stepped down as President and Chief Executive Officer, effective immediately. He has also resigned as a Director of AnorMED. Dr. Abrams has served as the Company’s President and CEO since founding the Company in 1996.

The Board has engaged the executive search firm of Russell Reynolds to immediately commence a search for a new President and CEO with significant experience and skills in the development and commercialization of healthcare products.

During this transition, the current Chairman of the Board, Kenneth Galbraith, will serve as Interim CEO. Mr. Galbraith has almost 20 years of experience in the biotechnology sector, including serving as Executive Vice-President and Chief Financial Officer for QLT Inc. until October 2000. Mr. Galbraith was elected to the Board of AnorMED in April 2006.

“Mike Abrams has dedicated the past ten years to building a leading biopharmaceutical company with talented employees and a number of excellent product opportunities, including MOZOBILTM , which is currently in Phase III clinical studies in North America and Europe,” said Mr. Galbraith.

“The new Board of Directors strongly believes that MOZOBIL represents a substantial opportunity for AnorMED to transform itself from a research organization into a pharmaceutical development and commercialization company. With top-line data from the current MOZOBIL clinical studies expected to be available within the next twelve months, the Board and Dr. Abrams agreed that now was the appropriate time to recruit new executive leadership with a different set of skills and experience to execute the strategic direction approved by the Board.”

The Board has also appointed Paul Brennan, the Company’s Vice President, Business Development, as Acting President. Mr. Brennan, who joined AnorMED in May 2002 from Astra Zeneca, has substantial experience in business development and regulatory affairs in the pharmaceutical industry, in both North America and Europe. Mr. Brennan will work with the existing management team in overseeing the Company’s day-to-day operations until a new President and CEO is in place. He will also be appointed as President of AnorMED (UK) Inc. and have primary management responsibility for expanding the Company’s operations in the EU.

“It is the belief of the Board that shareholder value can best be maximized through the timely completion of the final stages of MOZOBIL development and the implementation of a commercial strategy that provides timely access to MOZOBIL for the broadest class of patients in the most efficient manner on a global basis while retaining the largest portion possible of commercial value for AnorMED shareholders who have borne all of the development risk,” added Mr. Galbraith. “The Company expects to provide specific corporate goals for the 2007 fiscal year and an update on the progress of MOZOBIL and its other products under development around the middle of June, in conjunction with the release of its annual financial results for the fiscal year ended March 31, 2006.”

About MOZOBIL
MOZOBIL is a stem cell mobilizer used in stem cell transplants, a procedure used to restore the immune system of cancer patients who have had treatments that previously destroyed their immune cells. MOZOBIL works by triggering the rapid movement of stem cells out of the bone marrow and into circulating blood. Once in the circulating blood, the stem cells can be collected for use in a stem cell transplant. In Phase II studies, MOZOBIL consistently demonstrated the ability to help cancer patients generate more of their own stem cells, resulting in an increase in the potential for these patients to be able to undergo a stem cell transplant.

MOZOBIL is currently the subject of two Phase III clinical studies at 35 major centres in the U.S. involving 600 cancer patients with either non-Hodgkin’s Lymphoma or multiple myeloma and who are undergoing autologous stem cell transplantation as a part of their treatment. Both Phase III studies are randomized, double-blind, placebo controlled, comparative trials of MOZOBIL plus G-CSF versus placebo plus G-CSF, the current standard drug used to stimulate additional stem cells within bone marrow.

The Company expects to complete patient recruitment of the Phase III studies and three month follow-up of patients by the end of 2006 and announce top-line results from the studies in the first half of 2007. If successful, the results of these clinical studies would be the basis for filings in the United States, Canada, the EU and other countries seeking approval to market MOZOBIL for these indications.

About AnorMED Inc.
AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, oncology and HIV, based on the Company’s research into chemokine receptors.

The Company’s product pipeline includes MOZOBIL, currently in Phase III studies in cancer patients undergoing stem cell transplants; AMD070, currently in Phase I/II studies in HIV patients; and several novel classes of compounds in pre-clinical development that target specific chemokine receptors known to be involved in a variety of diseases. Additional information on AnorMED Inc. is available on the Company’s website www.anormed.com.

Contact Information

Media Contacts

AnorMED Inc.

Contact via E-mail